AstraZeneca: 1 director

A director at AstraZeneca bought 1,500 shares at 126.796USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Moody's Ratings assigns A3 rating to Gilead's notes; stable outlook

Moody's Ratings (Moody´s) assigned an A3 rating to the new senior unsecured notes issuance of Gilead Sciences, Inc. ("Gilead"). There are no changes to Gilead's existing ratings including the A3 senior unsecured ratings, (P)A3 senior unsecured shelf or the stable outlook. Proceeds of the offering ...

AZN - Overdone – U/G to BUY (TP £120, 10pgs)

We upgrade AZN after we factor in what we believe is the worst-case China outcome and upgrade our 2025 sales following a strong Q3, leaving us just 2% below 2025 cons EBIT. Moreover, a strong Q3 shows the potential for robust revenue growth (ex-China) in 2025 & based on our conversations with investors, we now believe they are ready to start to look through the China issues, but we acknowledge the very likely risk that AZN will ultimately be drawn into the fraud investigations in China. Furtherm...

Keep calm and carry on

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/12/2024

...

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 12/11/2024

...

AstraZeneca : A better Q3 than anticipated, a change to the Dato regis...

>Q3 better than expected, Symbicort again delivers a positive surprise - AstraZeneca has just published results for Q3 2024 which proved better than expected. Revenue was up +21% at constant currency (cc) driven by the oncology (+22%), CVRM (+20%) and respiratory (+29%) franchise. We see no major difference vis-a-vis forecasts for the group’s core products but we would note an excellent performance over the quarter from Symbicort, as well as Tezspire which came in res...

AstraZeneca : Un T3 2024 meilleur qu’attendu, changement du process d’...

>Un T3 meilleur qu’attendu, Symbicort est de nouveau la bonne surprise - AZN vient de publier ses résultats du T3 24 qui se révèlent meilleurs qu’attendu. Les revenus sont en hausse de 21% à tcc tirés par sa franchise Oncologie (+22%), CVRM (+20%) et Respiratoire (+29%). Nous ne voyons pas de gros décalage vis-à-vis des attentes dans les produits core du groupe mais pouvons de nouveau souligner l’excellente performance de Symbicort ce trimestre, ainsi que de Tezspire ...

Strong operational Q3, but Dato-DXd hurts

AZN feeling the China blues

Gilead Sciences Inc: 2 directors

Two Directors at Gilead Sciences Inc sold/sold after exercising options 30,590 shares at between 91.280USD and 91.500USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...

ODDO BHF Small & MIDCAP MORNING NEWS - 06/11/2024

Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...

ODDO BHF Small & MIDCAP MORNING NEWS - 11/06/2024

Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/06/2024

Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 06/11/2024

Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...

AstraZeneca : The investigations in China continue to drag on the shar...

>The facts - Last week, we learned that the president of AZN China was cooperating with the local authorities as part of an ongoing investigation and more recently Bloomberg published an article with further details. According to the press, the investigation is focused on “aggressive sales tactics used for at least two of its oncology drugs, the lung cancer treatment Tagrisso and the immunotherapy treatment Imjud”.The media describe vendors who use unorthodox met...

AstraZeneca : Les investigations en Chine continuent de peser sur le t...

>Les faits - La semaine dernière, nous avons appris que le président Chine d'AZN coopérait avec les autorités locales dans le cadre d’une enquête en cours et plus récemment, Bloomberg a publié un article avec des détails supplémentaires. Selon les articles de presse, l'enquête porte sur « des tactiques de vente agressives utilisées pour au moins deux de ses médicaments oncologiques, le traitement du cancer du poumon Tagrisso et l'immunothérapie Imjud ».Les médias...

Obesity Thematic - A Deep-Dive into Amylin

In the coming days at Obesity Week, we will see multiple datasets from amylin assets that could help to further support our belief that amylin combinations could become a material MOA in the Obesity market. Ahead of the Cagrisema P3 readout, we dig deep into the potential for amylin and show: 1) It has a superior tolerability profile, 2) Could preserve lean muscle mass and 3) Could be neuroprotective. We analyse the majority of the clinical data available on these drugs & show that the full prom...

Gilead Sciences, Inc.: Update to credit analysis

Our credit view of this issuer reflects its status as a global market leader in HIV therapies, against its somewhat limited revenue diversity at the product and category level.

ODDO : Feedback from the MS Expert Access event: still many areas for ...

Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the a...